Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis & Investment Frameworks
Agios Pharmaceuticals, Inc. (AGIO) stock analysis on Invetso. Review Agios Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Agios Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Agios Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $2.22B
- Revenue: $54.03M
- ROE: -35.67%
- ROIC: -43.30%
- Dividend Yield: N/A
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Agios Pharmaceuticals, Inc. (AGIO) across the following frameworks:
- Agios Pharmaceuticals, Inc. 10Y Growth Potential
- Agios Pharmaceuticals, Inc. Scenario Analysis
- Agios Pharmaceuticals, Inc. Risks & Opportunities
- Agios Pharmaceuticals, Inc. Economic Moat
- Agios Pharmaceuticals, Inc. Business Model
- Agios Pharmaceuticals, Inc. Management
- Agios Pharmaceuticals, Inc. SWOT Analysis
- Agios Pharmaceuticals, Inc. Porter's 5 Forces
- Agios Pharmaceuticals, Inc. PESTLE Analysis
- Agios Pharmaceuticals, Inc. ESG Analysis